Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2008-08-19
2011-11-15
Carlson, Karen (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C530S350000
Reexamination Certificate
active
08058225
ABSTRACT:
The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors. Finally, the present invention relates to the uses of said polypeptide, variants thereof, nucleic acid sequences, vectors and host cells, in particular for the treatment or prophylaxis of a subject infected by or exposed toStaphylococci.
REFERENCES:
patent: 5997862 (1999-12-01), Fischetti et al.
patent: 7608276 (2009-10-01), Masignani et al.
patent: 2007/0077235 (2007-04-01), Loomis et al.
patent: 2255561 (1992-11-01), None
Kuroda et al. 2001; Whole genome sequencing of meticillin-resistantStaphyloccus aureus. Lancet 357: 1225-1240.
Iandolo et al. 2002; Comparative analysis of the genomes of the terperate bacteriophages phi11, phi12, and phi13 ofStaphylococcus aureus8325. Gene 289: 109-118.
Kwan et al. .2005; The complete genomes and protons of 27Staphylococcus aureusbacteriophages. PNAS 102: 5174-5179.
Cheng et al., “Removal of group B Streptococci olonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme,”Antimicrob. Agents Chemother., 49:111-117, 2005.
Databank Accession No. NC—007793, Jul. 28, 2008.
Diep et al., “Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistantStaphylococcus aureus,” The Lancet, 367:731-739, 2006.
Entenza et al., “Therapeutic effects of bacteriophage Cpl-1 lysin againstStreptococcus pneumoniaeendocarditis in rats,”Antimicrob. Agents Chemother., 49:4789-4792, 2005.
Fischetti,BMC Oral Health, 6:16-19, 2006.
Loeffler et al., “Rapid killing ofStreptococcus pneumoniaewith a bacteriophage cell wall hydrolase,”Science, 294:2170-2172, 2001.
Lu et al., “Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges,”J. Biol. Chem., 281:549-558, 2006.
Nelson et al., “Prevention and elimination of upper respiratory colonization of mice by group A Streptococci by using a bacteriophage lytic enzyme,”Proc. Natl. Acad. Sci. USA, 98:4107-4112, 2001.
Schuch et al., “A bacteriolytic agent that detects and killsBacillus anthracis,” Nature, 418:884-889, 2002.
Biebl Manfred
Forchheim Michael
Grallert Holger
Philipp Anja
Carlson Karen
Fulbright & Jaworski
Hyglos Invest GmbH
LandOfFree
Proteins for use in human and animal Staphylococcus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteins for use in human and animal Staphylococcus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteins for use in human and animal Staphylococcus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4257978